Business Context and Reporting Period
Astro-Med, Inc. (NASDAQ: ALOT) filed an 8-K on August 20, 2003, reporting unaudited financial results for the second quarter ended August 2, 2003. The company manufactures high-tech specialty printing systems, electronic medical instrumentation, and test and measurement instruments.
Key Financial Metrics
| Metric | Q2 2003 | Q2 2002 | YTD 2003 | YTD 2002 |
|---|---|---|---|---|
| Net Sales | $14,023,000 | $12,970,000 | $27,237,000 | $24,412,000 |
| Net Income | $810,000 | $156,000 | $1,316,000 | ($477,000) |
| Diluted EPS | $0.18 | $0.04 | $0.30 | ($0.11) |
| Gross Margin | 41.5% | 37.4% | N/A | N/A |
| Operating Margin | 7.0% | N/A | N/A | N/A |
| Cash & Marketable Securities | $8,300,000 | N/A | N/A | N/A |
New orders for the quarter exceeded $14,500,000. The company declared a quarterly cash dividend of $0.04 per share.
Material Changes
- Revenue Growth: Second-quarter sales increased 8.1% year-over-year, reaching a record $14.0 million.
- Profitability Surge: Net income increased 419% year-over-year to $810,000, driven by margin expansion.
- Margin Improvement: Gross profit margins improved to 41.5% from 37.4% in the prior year and 38.2% in the previous quarter.
- Market Performance: Domestic sales grew 9% and export sales grew 26% (excluding foreign exchange impacts).
- Liquidity: Cash and marketable securities increased by $1,000,000 to $8,300,000 compared to the prior year-end.
Outlook, Commentary, and Risks
Management expressed satisfaction with the results, citing solid demand for new products including the QLS-4100 Xe and QLS-8100 Xe color printers, Comet EEG/PSG systems, and ToughWriter printers. The company noted that the balance sheet remains solid.
Risks and Contingencies: The filing includes a Safe Harbor statement noting that forward-looking statements are subject to risks and uncertainties. Actual results may vary due to factors detailed in the company's FY2003 annual report and other SEC filings.
Investor Verification Checklist
- Verify the sustainability of the 41.5% gross margin improvement against future cost structures.
- Confirm the conversion rate of the $14.5 million in new orders to future revenue.
- Review the specific product mix driving the 26% export growth to assess currency risk exposure.
- Check subsequent filings for any changes in the declared dividend or liquidity position.